361 Capital LLC bought a new stake in Halyard Health, Inc. (NYSE:HYH) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 40,300 shares of the medical instruments supplier’s stock, valued at approximately $1,815,000. 361 Capital LLC owned 0.09% of Halyard Health as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in HYH. Goldman Sachs Group Inc. boosted its position in shares of Halyard Health by 242.8% in the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after acquiring an additional 1,320,735 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Halyard Health by 19.3% in the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after acquiring an additional 507,893 shares during the period. Northern Trust Corp boosted its position in shares of Halyard Health by 41.2% in the second quarter. Northern Trust Corp now owns 1,510,297 shares of the medical instruments supplier’s stock valued at $59,324,000 after acquiring an additional 440,639 shares during the period. Koch Industries Inc. bought a new stake in shares of Halyard Health in the second quarter valued at about $297,000. Finally, JPMorgan Chase & Co. lifted its position in Halyard Health by 23.9% during the second quarter. JPMorgan Chase & Co. now owns 878,558 shares of the medical instruments supplier’s stock worth $34,509,000 after purchasing an additional 169,194 shares during the period. 91.73% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “361 Capital LLC Invests $1.82 Million in Halyard Health, Inc. (HYH)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/19/361-capital-llc-invests-1-82-million-in-halyard-health-inc-hyh.html.
Several research firms recently weighed in on HYH. Stifel Nicolaus reaffirmed a “buy” rating and set a $52.00 price objective on shares of Halyard Health in a research report on Friday, November 3rd. Zacks Investment Research cut shares of Halyard Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. KeyCorp reaffirmed a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th. Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Finally, TheStreet cut shares of Halyard Health from a “b-” rating to a “c+” rating in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Halyard Health presently has an average rating of “Buy” and a consensus price target of $44.00.
Halyard Health, Inc. (NYSE:HYH) traded up $0.24 on Friday, reaching $45.69. 203,883 shares of the company traded hands, compared to its average volume of 498,349. Halyard Health, Inc. has a 1-year low of $35.24 and a 1-year high of $50.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19. The company has a market capitalization of $2,139.94, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.47 and a beta of 1.69.
Halyard Health (NYSE:HYH) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.13. The firm had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.48 earnings per share. sell-side analysts anticipate that Halyard Health, Inc. will post 2.08 EPS for the current fiscal year.
Halyard Health Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health, Inc. (NYSE:HYH).
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.